STUDIES ON RELATIONSHIP BETWEEN HISTOLOGY, TUMOR MARKERS (Prostatic Acid Phosphatase·Prostate Specific Antigen·γ-Seminoprotein·Leu-7) AND CLINICAL COURSE IN PROSTATE CANCER
We are interested in the therapeutic response to chemotherapy and radiotherapy of relapsed prostate cancer. In 9 cases of prostate cancer treated by endocrine therapy, tumor markers (PAP·PA·γ-Sm·Leu-7) and cell types at the start of endocrine therapy and that taken at a hormone independent point wer...
Gespeichert in:
| Veröffentlicht in: | Nippon Hinyokika Gakkai zasshi 1990/05/20, Vol.81(5), pp.680-685 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 685 |
|---|---|
| container_issue | 5 |
| container_start_page | 680 |
| container_title | Nippon Hinyokika Gakkai zasshi |
| container_volume | 81 |
| creator | Tanahashi, Toyoko Namba, Katsuichi Murao, Tsuyoshi |
| description | We are interested in the therapeutic response to chemotherapy and radiotherapy of relapsed prostate cancer. In 9 cases of prostate cancer treated by endocrine therapy, tumor markers (PAP·PA·γ-Sm·Leu-7) and cell types at the start of endocrine therapy and that taken at a hormone independent point were compared between prostatic tissue obtained. All cases had a period of response to endocrine therapy, but subsequently relapsed. The results were divided into the following 3 groups: Group I (changed cell type·decreased positive rate of markers) had the shortest response duration to endocrine therapy and there was no response to chemotherapy; Group II (unchanged cell type·decreased positive rate of markers) had a long response duration and slow progression under endocrine therapy; Group III (unchanged cell type·unchanged positive rate of markers) was chemo- or radiotherapy sensitive during post-endocrine therapy relapse. These results suggest that this is an effective method which dictated the choice of treatment method and allowed an approximate prognosis for relapsed prostate cancer previously treated by endocrine therapy. |
| doi_str_mv | 10.5980/jpnjurol1989.81.680 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_5980_jpnjurol1989_81_680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1695956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3250-9fbf49372374e336e06f8dafb2f2f063f70f9dc9819120dfee07ed00658108763</originalsourceid><addsrcrecordid>eNplUcFum0AQXVWNUivNF1SV9thKwd1lDeweKdnGKAQsFqvqCWGYjbFsQIAP_atKPeSeD8g3ZS2ipFIvM9K8eU8z7yH0iZK5Izj5tuua3bFv91RwMed07nLyDs0o5wvLo5S8RzNCbGo5Nvc-oMthqDeEUY_bnLFzdE5d4QjHnaE_Kltfh1LhJMapjPwsTGK1DFf4u8x-ShnjZaiyJEpufl3hbH2XpPjOT29lqvCXVd8OYzHWJfbLusKrbTt022IsBnh8eMEAqw7KWp92mrG-h-bx4emvpeBQN23XtyPUZhLB0fK-Yj--xkEUxmHgRzhI1qmSOIzxKk1U5mcSB34cyPQjOtPFfoDLl36B1j9kFiwtc-OJaZXMdogl9EYvBPNs5i2AMReIq3lV6I2tbU1cpj2iRVUKTgW1SaUBiAcVIa7DKeGeyy4Qm3RL88rQg867vj4U_e-ckvyUQP5vAjmnuUnAsD5PrO64OUD1xpn8NvhywnfGnnt4xYve-LiH_zSdqRjp15VyW_Q5NOwZ6-6b8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>STUDIES ON RELATIONSHIP BETWEEN HISTOLOGY, TUMOR MARKERS (Prostatic Acid Phosphatase·Prostate Specific Antigen·γ-Seminoprotein·Leu-7) AND CLINICAL COURSE IN PROSTATE CANCER</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tanahashi, Toyoko ; Namba, Katsuichi ; Murao, Tsuyoshi</creator><creatorcontrib>Tanahashi, Toyoko ; Namba, Katsuichi ; Murao, Tsuyoshi</creatorcontrib><description>We are interested in the therapeutic response to chemotherapy and radiotherapy of relapsed prostate cancer. In 9 cases of prostate cancer treated by endocrine therapy, tumor markers (PAP·PA·γ-Sm·Leu-7) and cell types at the start of endocrine therapy and that taken at a hormone independent point were compared between prostatic tissue obtained. All cases had a period of response to endocrine therapy, but subsequently relapsed. The results were divided into the following 3 groups: Group I (changed cell type·decreased positive rate of markers) had the shortest response duration to endocrine therapy and there was no response to chemotherapy; Group II (unchanged cell type·decreased positive rate of markers) had a long response duration and slow progression under endocrine therapy; Group III (unchanged cell type·unchanged positive rate of markers) was chemo- or radiotherapy sensitive during post-endocrine therapy relapse. These results suggest that this is an effective method which dictated the choice of treatment method and allowed an approximate prognosis for relapsed prostate cancer previously treated by endocrine therapy.</description><identifier>ISSN: 0021-5287</identifier><identifier>EISSN: 1884-7110</identifier><identifier>DOI: 10.5980/jpnjurol1989.81.680</identifier><identifier>PMID: 1695956</identifier><language>eng ; jpn</language><publisher>Japan: THE JAPANESE UROLOGICAL ASSOCIATION</publisher><subject>Acid Phosphatase - analysis ; Aged ; Aged, 80 and over ; Antigens, Differentiation - analysis ; Biomarkers, Tumor - analysis ; CD57 Antigens ; clinical course ; Combined Modality Therapy ; Diethylstilbestrol - therapeutic use ; Gonadotropin-Releasing Hormone - therapeutic use ; Humans ; immunohistopatholog ; Male ; Middle Aged ; Neoplasm Staging ; Orchiectomy ; prostate cancer ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - therapy ; Prostatic Secretory Proteins ; Proteins - analysis ; Recurrence ; Seminal Plasma Proteins</subject><ispartof>The Japanese Journal of Urology, 1990/05/20, Vol.81(5), pp.680-685</ispartof><rights>Japanese Urological Association</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3250-9fbf49372374e336e06f8dafb2f2f063f70f9dc9819120dfee07ed00658108763</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1695956$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanahashi, Toyoko</creatorcontrib><creatorcontrib>Namba, Katsuichi</creatorcontrib><creatorcontrib>Murao, Tsuyoshi</creatorcontrib><title>STUDIES ON RELATIONSHIP BETWEEN HISTOLOGY, TUMOR MARKERS (Prostatic Acid Phosphatase·Prostate Specific Antigen·γ-Seminoprotein·Leu-7) AND CLINICAL COURSE IN PROSTATE CANCER</title><title>Nippon Hinyokika Gakkai zasshi</title><addtitle>Jpn. j. urol</addtitle><description>We are interested in the therapeutic response to chemotherapy and radiotherapy of relapsed prostate cancer. In 9 cases of prostate cancer treated by endocrine therapy, tumor markers (PAP·PA·γ-Sm·Leu-7) and cell types at the start of endocrine therapy and that taken at a hormone independent point were compared between prostatic tissue obtained. All cases had a period of response to endocrine therapy, but subsequently relapsed. The results were divided into the following 3 groups: Group I (changed cell type·decreased positive rate of markers) had the shortest response duration to endocrine therapy and there was no response to chemotherapy; Group II (unchanged cell type·decreased positive rate of markers) had a long response duration and slow progression under endocrine therapy; Group III (unchanged cell type·unchanged positive rate of markers) was chemo- or radiotherapy sensitive during post-endocrine therapy relapse. These results suggest that this is an effective method which dictated the choice of treatment method and allowed an approximate prognosis for relapsed prostate cancer previously treated by endocrine therapy.</description><subject>Acid Phosphatase - analysis</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Differentiation - analysis</subject><subject>Biomarkers, Tumor - analysis</subject><subject>CD57 Antigens</subject><subject>clinical course</subject><subject>Combined Modality Therapy</subject><subject>Diethylstilbestrol - therapeutic use</subject><subject>Gonadotropin-Releasing Hormone - therapeutic use</subject><subject>Humans</subject><subject>immunohistopatholog</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Orchiectomy</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Prostatic Secretory Proteins</subject><subject>Proteins - analysis</subject><subject>Recurrence</subject><subject>Seminal Plasma Proteins</subject><issn>0021-5287</issn><issn>1884-7110</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplUcFum0AQXVWNUivNF1SV9thKwd1lDeweKdnGKAQsFqvqCWGYjbFsQIAP_atKPeSeD8g3ZS2ipFIvM9K8eU8z7yH0iZK5Izj5tuua3bFv91RwMed07nLyDs0o5wvLo5S8RzNCbGo5Nvc-oMthqDeEUY_bnLFzdE5d4QjHnaE_Kltfh1LhJMapjPwsTGK1DFf4u8x-ShnjZaiyJEpufl3hbH2XpPjOT29lqvCXVd8OYzHWJfbLusKrbTt022IsBnh8eMEAqw7KWp92mrG-h-bx4emvpeBQN23XtyPUZhLB0fK-Yj--xkEUxmHgRzhI1qmSOIzxKk1U5mcSB34cyPQjOtPFfoDLl36B1j9kFiwtc-OJaZXMdogl9EYvBPNs5i2AMReIq3lV6I2tbU1cpj2iRVUKTgW1SaUBiAcVIa7DKeGeyy4Qm3RL88rQg867vj4U_e-ckvyUQP5vAjmnuUnAsD5PrO64OUD1xpn8NvhywnfGnnt4xYve-LiH_zSdqRjp15VyW_Q5NOwZ6-6b8w</recordid><startdate>199005</startdate><enddate>199005</enddate><creator>Tanahashi, Toyoko</creator><creator>Namba, Katsuichi</creator><creator>Murao, Tsuyoshi</creator><general>THE JAPANESE UROLOGICAL ASSOCIATION</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199005</creationdate><title>STUDIES ON RELATIONSHIP BETWEEN HISTOLOGY, TUMOR MARKERS (Prostatic Acid Phosphatase·Prostate Specific Antigen·γ-Seminoprotein·Leu-7) AND CLINICAL COURSE IN PROSTATE CANCER</title><author>Tanahashi, Toyoko ; Namba, Katsuichi ; Murao, Tsuyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3250-9fbf49372374e336e06f8dafb2f2f063f70f9dc9819120dfee07ed00658108763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>1990</creationdate><topic>Acid Phosphatase - analysis</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Differentiation - analysis</topic><topic>Biomarkers, Tumor - analysis</topic><topic>CD57 Antigens</topic><topic>clinical course</topic><topic>Combined Modality Therapy</topic><topic>Diethylstilbestrol - therapeutic use</topic><topic>Gonadotropin-Releasing Hormone - therapeutic use</topic><topic>Humans</topic><topic>immunohistopatholog</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Orchiectomy</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Prostatic Secretory Proteins</topic><topic>Proteins - analysis</topic><topic>Recurrence</topic><topic>Seminal Plasma Proteins</topic><toplevel>online_resources</toplevel><creatorcontrib>Tanahashi, Toyoko</creatorcontrib><creatorcontrib>Namba, Katsuichi</creatorcontrib><creatorcontrib>Murao, Tsuyoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Nippon Hinyokika Gakkai zasshi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanahashi, Toyoko</au><au>Namba, Katsuichi</au><au>Murao, Tsuyoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>STUDIES ON RELATIONSHIP BETWEEN HISTOLOGY, TUMOR MARKERS (Prostatic Acid Phosphatase·Prostate Specific Antigen·γ-Seminoprotein·Leu-7) AND CLINICAL COURSE IN PROSTATE CANCER</atitle><jtitle>Nippon Hinyokika Gakkai zasshi</jtitle><addtitle>Jpn. j. urol</addtitle><date>1990-05</date><risdate>1990</risdate><volume>81</volume><issue>5</issue><spage>680</spage><epage>685</epage><pages>680-685</pages><issn>0021-5287</issn><eissn>1884-7110</eissn><abstract>We are interested in the therapeutic response to chemotherapy and radiotherapy of relapsed prostate cancer. In 9 cases of prostate cancer treated by endocrine therapy, tumor markers (PAP·PA·γ-Sm·Leu-7) and cell types at the start of endocrine therapy and that taken at a hormone independent point were compared between prostatic tissue obtained. All cases had a period of response to endocrine therapy, but subsequently relapsed. The results were divided into the following 3 groups: Group I (changed cell type·decreased positive rate of markers) had the shortest response duration to endocrine therapy and there was no response to chemotherapy; Group II (unchanged cell type·decreased positive rate of markers) had a long response duration and slow progression under endocrine therapy; Group III (unchanged cell type·unchanged positive rate of markers) was chemo- or radiotherapy sensitive during post-endocrine therapy relapse. These results suggest that this is an effective method which dictated the choice of treatment method and allowed an approximate prognosis for relapsed prostate cancer previously treated by endocrine therapy.</abstract><cop>Japan</cop><pub>THE JAPANESE UROLOGICAL ASSOCIATION</pub><pmid>1695956</pmid><doi>10.5980/jpnjurol1989.81.680</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-5287 |
| ispartof | The Japanese Journal of Urology, 1990/05/20, Vol.81(5), pp.680-685 |
| issn | 0021-5287 1884-7110 |
| language | eng ; jpn |
| recordid | cdi_crossref_primary_10_5980_jpnjurol1989_81_680 |
| source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Acid Phosphatase - analysis Aged Aged, 80 and over Antigens, Differentiation - analysis Biomarkers, Tumor - analysis CD57 Antigens clinical course Combined Modality Therapy Diethylstilbestrol - therapeutic use Gonadotropin-Releasing Hormone - therapeutic use Humans immunohistopatholog Male Middle Aged Neoplasm Staging Orchiectomy prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - pathology Prostatic Neoplasms - therapy Prostatic Secretory Proteins Proteins - analysis Recurrence Seminal Plasma Proteins |
| title | STUDIES ON RELATIONSHIP BETWEEN HISTOLOGY, TUMOR MARKERS (Prostatic Acid Phosphatase·Prostate Specific Antigen·γ-Seminoprotein·Leu-7) AND CLINICAL COURSE IN PROSTATE CANCER |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A50%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=STUDIES%20ON%20RELATIONSHIP%20BETWEEN%20HISTOLOGY,%20TUMOR%20MARKERS%20(Prostatic%20Acid%20Phosphatase%C2%B7Prostate%20Specific%20Antigen%C2%B7%CE%B3-Seminoprotein%C2%B7Leu-7)%20AND%20CLINICAL%20COURSE%20IN%20PROSTATE%20CANCER&rft.jtitle=Nippon%20Hinyokika%20Gakkai%20zasshi&rft.au=Tanahashi,%20Toyoko&rft.date=1990-05&rft.volume=81&rft.issue=5&rft.spage=680&rft.epage=685&rft.pages=680-685&rft.issn=0021-5287&rft.eissn=1884-7110&rft_id=info:doi/10.5980/jpnjurol1989.81.680&rft_dat=%3Cpubmed_cross%3E1695956%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1695956&rfr_iscdi=true |